FAB
Comprehensive validation - Validated with various antibody drugs.
Simple and fast operation - No complicated washing steps, significantly reducing time.
High batch consistency - Strict control over raw materials and finished product quality, ensuring a stable supply.
Accurate and reliable results - High sensitivity with minimal matrix effects.
High throughput capability - Support multiple product specifications, ideal for high-throughput screening.
Fast completion - Results in just 1 hour.
Product Specifications
Assay Type | Competition-TR-FRET |
Format | 100T/500T |
Reactivity | Human |
Regulatory Status | RUO |
Assay Time | 1 hr |
Sample volume | 10 μL |
Product Overview
The Human PD-1 / PD-L1 Inhibitor Screening Kit (TR-FRET) is based on a homogeneous (no wash) competition TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer) to screening for inhibitors of human PD-1 binding to PD-L1 within 0.5-1 hours. It can also be used as a universal detection tool to identify the ability of human PD-1 to bind to human PD-L1.
Storage
1. Unopened kit should be stored at 2℃-8℃ upon receiving.
2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.
3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
Materials Provided
ID | Components | Size |
FRTP019-C01 | Human PD-L1 Protein Europium-chelate | 100 tests/500 tests |
FRTP019-C02 | FA Labeled Human PD-1 Protein | 100 tests/500 tests |
FRTP019-C03 | Anti-PD-L1 Antibody | 30 μg/100 tests 150 μg/500 tests |
DB-04 | TR-FRET Sample Dilution Buffer, pH7.4 | 50 mL/100 tests & 500 tests |
DB-05 | TR-FRET Detection Buffer, pH7.4 | 50 mL/100 tests & 500 tests |
Assay Principles
This Human PD-1 / PD-L1 Inhibitor Screening Kit (TR-FRET) is based on TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer). Use a mixture of biotinylated human PD-L1 and Europium-chelate labeled streptavidin as the donor and FA labeled human PD-1 as the acceptor.
— In the absence of inhibitors for human PD-L1 binding to human PD-1, the donor and acceptor are in close proximity due to the binding of human PD-L1 and human PD-1. Upon excitation with a specific light source, the donor emits a 620 nm signal, which is absorbed by the acceptor, resulting in a 665 nm emission.
— In the presence of inhibitors that block the binding of human PD-L1 to human PD-1, the donor-acceptor interaction is disrupted, preventing FRET from occurring.
China
